Clinical Trial: An open-label, multicenter, phase I/II study evaluating the safety, tolerability, pharmacokinetic profile, and efficacy of ICP-B381 in participants with advanced solid tumors (China)

China, Oct. 30 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'An open-label, multicenter, phase I/II study evaluating the safety, tolerability, pharmacokinetic profile, and efficacy of ICP-B381 in participants with advanced solid tumors'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600135484

Registration Time: 2026/10/30

Type: Interventional study

Primary Sponsor: Fudan University Shanghai Cancer Center

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=349899

Published by HT Digital Content Services with permission from Health Daily Digest....